Whether MSD Korea will be able to make progress in extending reimbursement for its cancer immunotherapy Keytruda for the 13 additional indications it had applied for is receiving attention.

According to industry sources, 3 indications of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) are expected to be deliberated by the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee on the 22nd.

Although the company applied for reimbursement of its 13 indications in bulk, the specific indications are expected to be deliberated separately. In October, its 3 applications for esophageal cancer, endometrial, and colorectal cancer were presented for deliberation